Uncover key drivers, emerging technologies, and competitive movements shaping the interventional oncology market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Interventional Oncology Market Be Worth By 2029?

The interventional oncology market has shown significant expansion in recent years. Its size is expected to increase from $2.49 billion in 2024 to $2.72 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.2%. The historical drivers for this growth include the rising global prevalence of cancer, the increased embrace of minimally invasive procedures, greater healthcare spending in developing economies, an escalating demand for image-guided therapies, and enhanced recognition of the advantages of interventional oncology.

The interventional oncology market is projected to experience robust expansion over the coming years. This market is forecast to reach $3.82 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.8%. Factors driving this growth during the projected period include an increase in demand for outpatient oncology procedures, the expanding application of combination therapies alongside immuno-oncology, a rise in clinical trials for image-guided therapies, improved accessibility to interventional oncology in developing markets, and the increasingly significant role of precision medicine in treatment strategy. Key trends anticipated within the forecast timeframe encompass progress in image-guided ablation technologies, the creation of diagnostic tools powered by artificial intelligence, novel targeted drug-delivery systems, enhancements in minimally invasive treatment devices, and the formulation of customized oncology treatment solutions.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27318&type=smp

What Market Forces Are Contributing To The Growth Of The Interventional Oncology Market?

The rising incidence of cancer is anticipated to drive the expansion of the interventional oncology market in the coming years. Cancer prevalence denotes the aggregate count of individuals, both recently and previously diagnosed, who are currently living with a history of the disease at a given moment. This increase in cancer prevalence stems from lifestyle factors such as inadequate nutrition, tobacco use, alcohol consumption, and exposure to environmental toxins, all of which heighten the chances of developing various cancers. Interventional oncology assists in treating cancer through minimally invasive, targeted approaches that concentrate directly on tumors. It enhances patient results by minimizing harm to healthy cells and offering quicker recovery periods compared to conventional treatments. As an illustration, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that cancer diagnoses in Australia reached 160,570 in 2022, representing a rise of 3,789 cases from 156,781 in 2021. Consequently, the growing occurrence of cancer is a key factor propelling the development of the interventional oncology market.

Which Segments Define The Structure Of The Interventional Oncology Market?

The interventional oncology market covered in this report is segmented

1) By Type: Radiation Therapy Devices, Ablation Devices, Embolization Devices

2) By Technology Type: Ultrasound, Computed Tomography Guided, Magnetic Resonance-Guided

3) By Procedure: Tumor Ablation, Tumor Biopsy, Vascular Interventions, Palliative Care

4) By Application Areas: Liver Cancer, Lung Cancer, Kidney Cancer, Pancreatic Cancer, Prostate Cancer

5) By End-Users: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Research And Academic Institutions

Subsegments:

1) By Radiation Therapy Devices: Linear Accelerators, Proton Therapy Systems, Brachytherapy Devices

2) By Ablation Devices: Radiofrequency Ablation Devices, Microwave Ablation Devices, Cryoablation Devices, Irreversible Electroporation Systems

3) By Embolization Devices: Microspheres, Coil Embolization Devices, Liquid Embolic Agents, Embolic Protection Devices

What Strategic Shifts And Innovations Are Influencing The Interventional Oncology Market?

Major companies in the interventional oncology market are concentrating on developing advanced products, such as microcatheter-based embolization systems, to deliver precise, targeted cancer therapy while minimizing harm to surrounding healthy tissue. Microcatheter-based embolization systems are medical devices that use tiny, flexible catheters to precisely deliver embolic agents into blood vessels to block or reduce blood flow, typically for treating tumors, vascular malformations, or bleeding. For instance, in March 2025, Terumo Corporation, a Japan-based medical device company, launched the Occlusafe balloon occlusion catheter, which is based on its advanced Balloon-TACE (B-TACE) therapy for the treatment of liver cancer, particularly hepatocellular carcinoma (HCC). This specialized microcatheter utilizes the pressure gradient effect to redirect blood flow and access the microcirculation, thereby enabling higher concentrations of therapeutic agents at the tumor site and minimizing off-target embolization. This targeted approach aims to improve clinical outcomes in difficult-to-treat liver cancer cases by enhancing drug delivery precision and offering improved visualization during procedures.

Which Firms Are Making The Biggest Impact In The Interventional Oncology Market?

Major companies operating in the interventional oncology market are Johnson & Johnson, Siemens Healthineers AG, Stryker Corporation, GE HealthCare Technologies Inc., Boston Scientific Corporation, Terumo Corporation, Hologic Inc., Teleflex Incorporated, Lantheus Holdings Inc., Penumbra Inc., Merit Medical Systems Inc., Guerbet S.A, Asahi Intecc Co. Ltd., AngioDynamics Inc., Sirtex Medical Limited., Delcath Systems Inc., ABK Biomedical Inc., Profound Medical Inc., IceCure Medical Ltd., Minimax Medical Holding Group.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/interventional-oncology-global-market-report

Which Region Is Forecasted To Lead The Interventional Oncology Market In The Coming Years?

North America was the largest region in the interventional oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional oncology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27318&type=smp

Browse Through More Reports Similar to the Global Interventional Oncology Market 2025, By The Business Research Company

Motor Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/motor-insurance-global-market-report

Renewable Energy Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renewable-energy-insurance-global-market-report

Automotive Usage Based Insurance Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/automotive-usage-based-insurance-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.